60 Degrees Pharmaceuticals Inc (SXTP)

$1.45 -0.03 (-2.03%)
Market Cap 6.08M
Revenue (ttm) 680,000.00
Net Income (ttm) -7.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,169.12%
Debt to Equity Ratio 0.00
Volume 40,000
Avg Vol 86,572
Day's Range N/A - N/A
Shares Out 4.10M
Stochastic %K 50%
Beta 2.79
Analysts Sell
Price Target $3.00

Company Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidi...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 327 5422
Address:
1025 Connecticut Avenue NW, Suite 1000, Washington, United States
Love_To_Learn
Love_To_Learn Oct. 7 at 11:52 AM
$SXTP NEED U SHORTLY
0 · Reply
GhostAtlas
GhostAtlas Oct. 3 at 2:09 AM
$SXTC $LODE $SXTP $SOAR *
0 · Reply
Ninjaman
Ninjaman Oct. 2 at 10:27 AM
$CIGL reminds me of that garbage stock $SXTP beware it spiked in like one 15 minute candle and dropped for 2 months straight and just faded
0 · Reply
Goatcheese
Goatcheese Sep. 29 at 9:08 PM
$SXTP well at least there’s no funds currently shorting
0 · Reply
Goatcheese
Goatcheese Sep. 29 at 9:05 PM
$SXTP I’m usually excited about 10% daily gain, but when you’re underwater it’s sublime
0 · Reply
DARKP00L
DARKP00L Sep. 29 at 5:22 PM
$SXTP this stock is attracting a lot of interest. Be prepared for possible changes!
0 · Reply
Tryitin
Tryitin Sep. 28 at 3:07 PM
$SXTP Plan to add more after the outcome of the meeting results on Oct 9. I am still positive abut their clinical trails and here for long term.
0 · Reply
moreFORless
moreFORless Sep. 26 at 5:03 PM
$SXTP Got the voting doc's in mail yesterday, dilution by 1\4 million share on agenda. Still holding on to the ship as I'm neutral on this ticker.
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 17 at 7:25 PM
$SXTP u gonna get bumpy soonish volatility so take a xanax
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 16 at 7:35 PM
$SXTP What are you doing here? Med Admin Tech Stock $HCTI released good NASDAQ Compliance, late yesterday, and they have some powerful Partnerships you might be interested in. Trading was in the BILLIONS, a little over a month ago. Don't miss the Run up.
0 · Reply
Latest News on SXTP
60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:02 AM EDT - 5 weeks ago

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 8:31 AM EDT - 6 weeks ago

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Aug 19, 2025, 8:54 AM EDT - 7 weeks ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

Aug 13, 2025, 4:14 PM EDT - 7 weeks ago

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Jul 16, 2025, 4:01 PM EDT - 2 months ago

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

Jul 15, 2025, 9:10 AM EDT - 3 months ago

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

Jul 15, 2025, 7:01 AM EDT - 3 months ago

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Jun 4, 2025, 8:56 AM EDT - 4 months ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Jun 3, 2025, 8:49 AM EDT - 4 months ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025, 4:31 PM EDT - 5 months ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 22, 2025, 8:44 AM EDT - 6 months ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 10, 2025, 8:31 AM EDT - 6 months ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Apr 8, 2025, 8:31 AM EDT - 6 months ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 21, 2025, 9:00 AM EST - 8 months ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 20, 2025, 10:36 AM EST - 8 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 11, 2025, 12:59 PM EST - 8 months ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 6, 2025, 2:07 PM EST - 8 months ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 8 months ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 8 months ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 28, 2025, 8:01 AM EST - 9 months ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Jan 8, 2025, 8:02 AM EST - 9 months ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 23, 2024, 8:57 AM EST - 10 months ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 11, 2024, 8:56 AM EST - 10 months ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Dec 2, 2024, 4:05 PM EST - 11 months ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 11 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Nov 14, 2024, 2:31 PM EST - 11 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Oct 3, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

Sep 12, 2024, 7:19 AM EDT - 1 year ago

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

HYLN COCH

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Sep 4, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 28, 2024, 2:48 PM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 14, 2024, 11:01 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 12, 2024, 9:12 AM EDT - 1 year ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

Aug 6, 2024, 9:26 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

Jul 25, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Jul 19, 2024, 8:29 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Jul 9, 2024, 6:31 AM EDT - 1 year ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Jun 27, 2024, 7:59 AM EDT - 1 year ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

May 30, 2024, 7:59 AM EDT - 1 year ago

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

May 20, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

May 15, 2024, 1:45 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

May 8, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

May 2, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

Apr 3, 2024, 7:58 AM EDT - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

Mar 14, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Feb 20, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Feb 8, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 31, 2024, 12:00 PM EST - 1 year ago

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

Jan 31, 2024, 11:15 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 30, 2024, 9:45 AM EST - 1 year ago

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

Jan 30, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

Love_To_Learn
Love_To_Learn Oct. 7 at 11:52 AM
$SXTP NEED U SHORTLY
0 · Reply
GhostAtlas
GhostAtlas Oct. 3 at 2:09 AM
$SXTC $LODE $SXTP $SOAR *
0 · Reply
Ninjaman
Ninjaman Oct. 2 at 10:27 AM
$CIGL reminds me of that garbage stock $SXTP beware it spiked in like one 15 minute candle and dropped for 2 months straight and just faded
0 · Reply
Goatcheese
Goatcheese Sep. 29 at 9:08 PM
$SXTP well at least there’s no funds currently shorting
0 · Reply
Goatcheese
Goatcheese Sep. 29 at 9:05 PM
$SXTP I’m usually excited about 10% daily gain, but when you’re underwater it’s sublime
0 · Reply
DARKP00L
DARKP00L Sep. 29 at 5:22 PM
$SXTP this stock is attracting a lot of interest. Be prepared for possible changes!
0 · Reply
Tryitin
Tryitin Sep. 28 at 3:07 PM
$SXTP Plan to add more after the outcome of the meeting results on Oct 9. I am still positive abut their clinical trails and here for long term.
0 · Reply
moreFORless
moreFORless Sep. 26 at 5:03 PM
$SXTP Got the voting doc's in mail yesterday, dilution by 1\4 million share on agenda. Still holding on to the ship as I'm neutral on this ticker.
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 17 at 7:25 PM
$SXTP u gonna get bumpy soonish volatility so take a xanax
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 16 at 7:35 PM
$SXTP What are you doing here? Med Admin Tech Stock $HCTI released good NASDAQ Compliance, late yesterday, and they have some powerful Partnerships you might be interested in. Trading was in the BILLIONS, a little over a month ago. Don't miss the Run up.
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 12 at 4:31 PM
$SXTP need to quicken your moveme3nt with everything going on n beud in a bit of a stuck mode temp due to supg
0 · Reply
redog677
redog677 Sep. 12 at 11:19 AM
$SXTP AND coming soon to you a R/S!!!!!
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 3 at 9:16 PM
$SXTP $SBFM $OST splitting u 3 up!
1 · Reply
redog677
redog677 Sep. 3 at 3:47 PM
$SXTP yesterday we finally broke out of the sideways channel.
0 · Reply
redog677
redog677 Sep. 3 at 3:46 PM
$SXTP On the daily we have a bullish divergence.
0 · Reply
LarryFeelTheHeaton
LarryFeelTheHeaton Sep. 3 at 3:39 PM
$SXTP
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 3 at 11:17 AM
$SXTP need to change u up b4 bEUD
0 · Reply
JarvisFlow
JarvisFlow Sep. 3 at 11:00 AM
Ascendiant Capital has adjusted their stance on 60 Degrees ( $SXTP ), setting the rating to Buy with a target price of 7 → 3.
0 · Reply
kshonstocks
kshonstocks Aug. 29 at 3:11 PM
heres one that shd work from scans--$SXTP off the bottom play
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Aug. 28 at 11:10 PM
$SXTP Watching this one. Giving off big gap up vibes. Current after-hours price is $1.31 on 8/28/25.
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 28 at 1:54 PM
$SXTP need to figure something out for u for short term let me see
1 · Reply
RedDogSailor
RedDogSailor Aug. 27 at 7:22 PM
$SXTP Solid company, growing revenue.
0 · Reply